Equity Details
Price & Market Data
Price: $0.237
Daily Change: -$0.0063 / 2.66%
Daily Range: $0.222 - $0.255
Market Cap: $3,454,465
Daily Volume: 3,823,613
Performance Metrics
1 Week: -7.81%
1 Month: -52.06%
3 Months: -78.41%
6 Months: -81.40%
1 Year: -97.18%
YTD: -78.38%
About AIM ImmunoTech Inc. (AIM)
Latest market trends for AIM ImmunoTech Inc. (AIM). The stock is priced at 0.237, showing a daily shift of -$0.0063 / 2.66%. Market cap: 3,454,465. All performance data is provided for your review.
Company Details
Employees: 19
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
